Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)

The honest answer: Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management since 2021 and for cardiovascular-event reduction since 2024. Retatrutide (Eli Lilly LY3437943) is investigational — TRIUMPH-1 pivotal data exist only via Lilly press release and the ADA 86th Scientific Sessions (May 2026), with no peer-reviewed Phase 3 publication yet^[1][2]. No head-to-head RCT exists; the magnitude comparison below is cross-trial.

At a glance

• Wegovy: FDA-approved June 2021 (chronic weight management); cardiovascular-event-reduction indication added March 2024 per SELECT ^[9][11].
• Retatrutide: investigational; no FDA approval as of May 2026; NDA not yet filed ^[1].
• Weight loss (cross-trial): retatrutide 12 mg -28.3% TBWL at 80 wk in TRIUMPH-1 ^[1] vs semaglutide 2.4 mg -14.9% TBWL at 68 wk in STEP-1 ^[6] — roughly 1.9x the Wegovy magnitude.
• Phase 2 retatrutide: Jastreboff 2023 NEJM reported ~24% TBWL at 12 mg / 48 wk (n=338) ^[3].
• Mechanism: Wegovy is single-class (GLP-1 only); retatrutide is triple-class (GIP + GLP-1 + glucagon).
• Cardiovascular outcomes: Wegovy has SELECT (20% relative MACE reduction; HR 0.80) ^[9]. Retatrutide cardiovascular outcomes trial (TRIUMPH-3) pending.
• Cost today: Wegovy WAC ~$1,349/28 days; NovoCare direct-pay tiers $499 pen / $399 high-dose pen / $149 oral pill. Retatrutide not commercially available.

Approval status — Wegovy FDA-approved 2021, retatrutide investigational

Wegovy (semaglutide 2.4 mg subcutaneous weekly) received FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity on June 4, 2021. In December 2022 the indication was extended to adolescents aged 12 and older. In March 2024 the FDA added a cardiovascular-event-reduction indication based on SELECT (Lincoff 2023 NEJM) for adults with established cardiovascular disease and obesity or overweight, irrespective of diabetes status ^[9][11]. As of the May 2026 DailyMed label revision, the Section 1 indications, Section 5 warnings, and Section 6.1 clinical trials adverse-reaction table are all in place ^[11].

Retatrutide remains investigational. Eli Lilly reported TRIUMPH-1 topline results in May 2026 via a PR Newswire investor release and a late-breaking presentation at the 86th American Diabetes Association Scientific Sessions ^[1][2]. The peer-reviewed manuscript has not yet been published. The TRIUMPH program design paper (Giblin 2026 DOM, PMID 41090431) ^[4] and the retatrutide lipid-and-metabolite secondary analysis (Pearson 2026 JCEM, PMID 42135195) ^[5] are PubMed-indexed, but the pivotal efficacy/safety paper is not. Eli Lilly has not yet filed a New Drug Application (NDA) or announced a US brand name. For broader context on the molecule, see our retatrutide triple agonist evidence review.

Weight loss head-to-head data

There is no head-to-head RCT of retatrutide vs semaglutide 2.4 mg. What follows is cross-trial: TRIUMPH-1 (retatrutide, n=2,339, 80 weeks)^[1][2] compared with STEP-1 (semaglutide 2.4 mg, n=1,961, 68 weeks) ^[6]. Trial populations and lifestyle interventions differ; the comparison is informative but not RCT-grade. Verified mean total body-weight reduction (TBWL):

Cross-trial, retatrutide 12 mg at 80 weeks (-28.3%) is approximately 1.9x larger than Wegovy 2.4 mg at 68 weeks (-14.9%). Even the retatrutide 4 mg starter dose (-19.0%) exceeds Wegovy's highest-dose result. The 104-week BMI-35+ extension reaches -30.3% TBWL, a magnitude historically associated with bariatric surgery. For the deeper TRIUMPH-1 dose-response breakdown plus responder rates, see our retatrutide TRIUMPH-1 before-and-after evidence article. For the within-Wegovy comparison to Ozempic, see our Wegovy vs Ozempic evidence review.

Mechanism — triple-class (GIP + GLP-1 + glucagon) vs single-class (GLP-1 only)

Wegovy is semaglutide, a long-acting GLP-1 receptor agonist. The single receptor mechanism drives satiety, slowed gastric emptying, and glucose-dependent insulin secretion — the established GLP-1 class effects underlying its 14.9% STEP-1 result ^[6].

Retatrutide engages three receptors:

• GLP-1 receptor — same satiety + gastric-emptying axis as semaglutide.
• GIP receptor — adipose and insulin-sensitizing axis (the same target tirzepatide uses in addition to GLP-1).
• Glucagon receptor — adds hepatic energy expenditure and lipolysis, the mechanism most cited as the source of the additional magnitude vs dual GIP/GLP-1 agents.

The Phase 2 trial (Jastreboff 2023 NEJM, PMID 37366315) ^[3] established proof-of-concept: retatrutide 12 mg produced approximately 24.2% TBWL at 48 weeks in 338 randomized adults with obesity (no T2D). Pearson 2026 JCEM ^[5] reported the lipid and metabolite secondary analysis consistent with the glucagon-receptor-driven hepatic-energy mechanism.

Trial duration + populations differ — caveats

Cross-trial comparison is informative but not RCT-grade. Important differences:

• Endpoint timing: TRIUMPH-1 primary endpoint at 80 weeks ^[1]; STEP-1 primary endpoint at 68 weeks^[6]. Longer treatment generally yields more loss; an 80-week vs 68-week comparison advantages retatrutide somewhat by duration alone.
• Baseline characteristics: STEP-1 enrolled adults with BMI 30+ (or 27+ with weight-related comorbidity), no T2D^[6]. TRIUMPH-1 enrolled a similar population, but the full pre-specified baseline tables await the peer-reviewed publication.
• Lifestyle intervention: both trials provided structured caloric reduction and physical-activity counseling; placebo arms lost roughly 2.2 to 2.4%, similar between trials.
• Citation rigor: STEP-1 is a published NEJM paper with full safety tables; TRIUMPH-1 topline is currently only available via Lilly press release plus ADA conference presentation, with the peer-reviewed manuscript pending.

For T2D-specific cross-trial framing, the STEP-2 trial (Davies 2021 Lancet, PMID 33667417) ^[7] reported semaglutide 2.4 mg produced -9.6% TBWL at 68 weeks in adults with T2D, smaller than the non-diabetic STEP-1 cohort. TRIUMPH-2 (retatrutide in T2D) topline has not yet been reported; comparison in the T2D population specifically remains unverified.

Side-effect profile cross-trial

GI adverse effects dominate both drugs:

• Wegovy nausea: approximately 44% in pooled adult obesity trials (Section 6.1 of the prescribing information) ^[11]. Diarrhea, vomiting, and constipation also above 20%.
• Retatrutide TRIUMPH-1 nausea: approximately 42.4% on 12 mg vs about 14.8% on placebo per Lilly topline ^[1]. Detailed AE tables (vomiting, diarrhea, constipation, discontinuation, serious adverse events) will accompany the peer-reviewed publication.
• Heart rate: Wegovy raises mean resting heart rate by 1 to 4 bpm per label Section 5.9; about 26% of treated adults had a peak heart-rate increase of 20 bpm or more at some visit during STEP-1/3/5 vs 16% on placebo ^[11]. See our Wegovy heart palpitations evidence article for the full safety framing. Retatrutide heart-rate data await the peer-reviewed TRIUMPH-1 publication.
• Retatrutide-specific signal: the Phase 2 trial (Jastreboff 2023) ^[3] reported a dose-dependent dysesthesia/paresthesia signal not described in semaglutide trials. Patients with peripheral neuropathy history should discuss this with their prescriber once retatrutide is available.

Cardiovascular outcomes — Wegovy has SELECT; retatrutide TRIUMPH-3 pending

Wegovy has a proven cardiovascular benefit. SELECT (Lincoff 2023 NEJM, PMID 37952131) randomized 17,604 adults with obesity and pre-existing cardiovascular disease but without diabetes to semaglutide 2.4 mg vs placebo, with mean follow-up 39.8 months^[9]. Primary result: 20% relative reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke); HR 0.80, 95% CI 0.72 to 0.90. This result drove the March 2024 FDA label expansion to a cardiovascular-event-reduction indication.

Retatrutide cardiovascular outcomes data do not yet exist. TRIUMPH-3 (the retatrutide cardiovascular outcomes trial in adults with cardiovascular disease) is part of the TRIUMPH program design (Giblin 2026 DOM) ^[4] and is ongoing. Until TRIUMPH-3 reads out, Wegovy is the only drug in this class with proven hard cardiovascular-event benefit in adults with obesity. For most patients with established cardiovascular disease, that fact alone tilts the decision toward an approved-and-CVOT-proven Wegovy regimen now, with retatrutide reserved as a future option pending TRIUMPH-3 readout and FDA approval.

Weight maintenance evidence on semaglutide also has a published trial: STEP-4 (Rubino 2021 JAMA, PMID 33755728) ^[8] randomized 803 patients who had completed a 20-week semaglutide run-in to continued semaglutide vs placebo through week 68; continued treatment produced an additional -7.9% TBWL vs +6.9% regain on placebo. Retatrutide maintenance data have not been published.

Real-world delivery rate caveat

Real-world TBWL across the GLP-1 class consistently runs well below pivotal-trial means. Gasoyan 2024 JAMA Network Open (PMID 39269703)^[10] analyzed 3,389 adults in a Cleveland Clinic cohort treated with injectable semaglutide or liraglutide and reported mean 1-year TBWL on semaglutide prescribed for obesity of 5.9% — compared with 17.3% in STEP-1, or roughly one-third of the pivotal-trial mean. Among patients with persistent medication coverage, the mean was 5.5%; among those with under 90 days coverage, only 1.8%.

Applied to retatrutide 12 mg, a realistic real-world expectation at 80 weeks is in the roughly 9 to 17% TBWL range for the average patient, with the most adherent subset approaching the upper end. The trial-vs-real-world gap is driven by missed doses, supply pauses, side-effect-driven discontinuations, and the absence of trial-level lifestyle counseling. The retatrutide cross-trial advantage over Wegovy will likely persist in real-world use, but the absolute magnitudes will be smaller than either trial reported.

Cost + availability today

Wegovy: published US WAC list price is approximately $1,349 per 28-day supply. Novo Nordisk operates NovoCare direct-pay tiers with a $499 self-pay rate for the pen (eligibility-dependent), a $399 high-dose pen tier, and a $149 oral pill tier where applicable. Commercial-insurance coverage commonly applies with prior authorization keyed to BMI 30+ or BMI 27+ with a comorbidity. The new cardiovascular-event-reduction indication has broadened payer coverage for adults with established cardiovascular disease.

Retatrutide: not commercially available. No FDA approval, no published list price, and no Lilly-operated direct-pay portal. Compounded retatrutide sits in a regulatory grey zone with no FDA approval to anchor §503A pharmacy compounding, no presence on the FDA Drug Shortage list, and no USP monograph. This is not a stable supply path the patient should rely on. For more detail on the approval pathway and pricing mechanisms, see our companion analysis of what will determine retatrutide pricing once approved.

Practical takeaway

For most patients in May 2026, the decision is between an FDA-approved, CVOT-proven, widely-available drug (Wegovy) today, and an investigational triple agonist with larger trial-magnitude weight loss (retatrutide) sometime in 2027 or later. The right answer depends on individual context — cardiovascular history, BMI category, coverage, prior GLP-1 experience, side-effect tolerance — and that decision belongs with the prescriber. The cross-trial magnitude advantage of retatrutide is real but is not RCT-grade evidence, and the real-world delivery gap will compress the difference. Wegovy today is not a placeholder; it is a drug with a proven 20% reduction in major adverse cardiovascular events ^[9] and a stable FDA label backed by four years of real-world use. For broader cross-class context see our retatrutide vs tirzepatide head-to-head evidence article.

Cross-trial magnitude chart